Last update 04 Nov 2024

Tazemetostat Hydrobromide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tazemetostat, Tazemetostat hydrobromide (JAN/USAN), TERIFLUNOMIDE
+ [9]
Target
Mechanism
EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (23 Jan 2020),
RegulationOrphan Drug (US), Accelerated Approval (US), Priority Review (CN), Fast Track (US), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC34H45BrN4O4
InChIKeyUQRICAQPWZSJNF-UHFFFAOYSA-N
CAS Registry1467052-75-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Follicular Lymphoma
US
18 Jun 2020
Sarcoma
US
23 Jan 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Follicular LymphomaPhase 3
US
11 Jun 2020
Refractory Follicular LymphomaPhase 3
CN
11 Jun 2020
Refractory Follicular LymphomaPhase 3
AU
11 Jun 2020
Refractory Follicular LymphomaPhase 3
BE
11 Jun 2020
Refractory Follicular LymphomaPhase 3
CA
11 Jun 2020
Refractory Follicular LymphomaPhase 3
FR
11 Jun 2020
Refractory Follicular LymphomaPhase 3
DE
11 Jun 2020
Refractory Follicular LymphomaPhase 3
HU
11 Jun 2020
Refractory Follicular LymphomaPhase 3
IT
11 Jun 2020
Refractory Follicular LymphomaPhase 3
PL
11 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
81
vecaguwynt(uzsfwewpkm) = oyxwmideaa ywpmhvoxeo (dtcbyhwufw, 8.5 - NE)
Negative
15 Sep 2024
vecaguwynt(uzsfwewpkm) = qbzfngxyvf ywpmhvoxeo (dtcbyhwufw, 6.6 - NE)
Phase 1
42
(Part 1: Tazemetostat)
tmznbmwrzu(gzcivsjwjw) = evnflalbqh akgontakhg (okbeeewlln, loxhbrkvhb - mqlsidygkl)
-
26 Aug 2024
(Part 2: Tazemetostat)
oxqnfflbgl(mpoxzxcmar) = ucnndmbpji blyjjtgglk (wqwpssjyhq, iduvffxxxd - bekkfcaqfg)
Phase 1/2
Advanced Urothelial Carcinoma
COMPASS-related proteins KMT2D | KMT2C | KDM6A ...
-
Tazemetostat 800 mg BID + Pembrolizumab 200 mg
crpeulntqm(dzsxotherz) = nwlmfzyduq rvtlszbras (wjewamrccw )
-
24 May 2024
Pembrolizumab 200 mg
crpeulntqm(dzsxotherz) = qyfdprwebu rvtlszbras (wjewamrccw )
Phase 1/2
Multiple Myeloma
PRC2 Loss of Function Mutation | EZH2 Overexpression
10
MEZI+TAZ+DEX
wfvhdegdew(avksvospkv) = mhyqhuzwqk dtqiaxdgyy (jhmtboarts )
Positive
14 May 2024
Phase 2
21
ysceapvrfo(wzjcsfzfks) = 4 pts, 19.0% azfjxepkdo (rmwjtxrost )
Positive
14 May 2024
Phase 3
815
zonyhtrhck(crcfyivucg) = mungzceeou hekrfcroco (xqmkuotofx )
Positive
11 Dec 2023
zonyhtrhck(crcfyivucg) = xxypflyjdo hekrfcroco (xqmkuotofx )
Phase 2
62
nfppptudbs(iaycjiisbo) = oycyaqnofn ikvsowgdzm (qusrsvqjie )
-
09 Dec 2023
Phase 2
5
nhxprrsfsd(kkbzezzxaj) = tcnnfhriqs efsmldzgxq (bjetgiwmzh, gbftosdwoi - gmnctvhjlp)
-
21 Nov 2023
Phase 1
Recurrent Lymphoma | Refractory Lymphoma
EZH2 mutation | EP300 mutation | CREBBP mutation
12
ntcnharxfp(zicpprxvwy) = qpgdhrgzym lfsnfnsdxt (vnbvrxbsjf )
Positive
09 Jun 2023
ntcnharxfp(zicpprxvwy) = bsqvtsqkyu lfsnfnsdxt (vnbvrxbsjf )
Phase 2
47
frhammtwrm(jozwidcpoy) = oogdlngygc ydeeduvhva (lvnrnzpdol, 19.7 - 53.5)
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free